Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
RBC BioscienceROCO:6848 +4.86%76 Gross Margin % is 45.48% as of Dec. 2025, which is 1% below its 10-year median of 45.77. GuruFocus rates ROCO:6848 with a GF Score™ of 76/100 and a GF Value™ of NT$19.91 (Fairly Valued). The stock has 7 warning signs investors should review. Among 732 Biotechnology companies, RBC Bioscience ranks worse than 63.52% on this metric.
Warren Buffett believes that firms with excellent long term economics tend to have consistently higher margins.
Durable competitive advantage creates a high Gross Margin % because of the freedom to price in excess of cost. Companies can be categorized by their Gross Margin %
1. Greater than 40% = Durable competitive advantage
2. Less than 40% = Competition eroding margins
3. Less than 20% = no sustainable competitive advantage
Consistency of Gross Margin is key
RBC Bioscience had a gross margin of 45.48% for the quarter that ended in Dec. 2025 => Durable competitive advantage
Be Aware
If a company loses its competitive advantages, usually its gross margin declines well before its sales declines. Watching Gross Margin % and Operating Margin % closely helps avoid value trap situations.
RBC Bioscience Gross Margin % Related Terms
RBC Bioscience Gross Margin % Historical Data
* Premium members only.
The historical data trend for RBC Bioscience's Gross Margin % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
ROCO:6848 vs VRTX, REGN, ALNY: Gross Margin % Comparison
For the Biotechnology subindustry, RBC Bioscience's Gross Margin %, along with its competitors' market caps and Gross Margin % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
RBC Bioscience Gross Margin % vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, RBC Bioscience's Gross Margin % distribution charts can be found below:
* The bar in red indicates where RBC Bioscience's Gross Margin % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
A positive Gross Profit is only the first step for a company to make a net profit. The gross profit needs to be big enough to also cover related labor, equipment, rental, marketing/advertising, research and development and a lot of other costs in selling the products.
RBC Bioscience (ROCO:6848) has a Gross Margin % of 45.48% as of Dec. 2025. Gross margin is the ratio of total gross profit to net sales. View historical data on RBC Bioscience and its competitors. This is near median its historical median of 45.77. Over the past decade, RBC Bioscience's Gross Margin % has ranged from 41.38 to 52.22. According to the industry distribution chart, RBC Bioscience ranks #465 out of 732 companies in the Biotechnology industry, placing it in the top 63.5%.
Is RBC Bioscience's Gross Margin % too high?
RBC Bioscience's current Gross Margin % of 45.48% is near median its 10-year median of 45.77. Over the past 10 years, this metric has ranged from a low of 41.38 to a high of 52.22. The Biotechnology industry median Gross Margin % is 60.91. RBC Bioscience's value of 45.48% is 25.3% below this industry median. Based on the distribution chart, RBC Bioscience ranks #465 out of 732 companies in the Biotechnology industry, which is below the industry midpoint. Overall, RBC Bioscience has a GF Score™ of 76/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does RBC Bioscience's Gross Margin % compare to VRTX and REGN?
According to the Biotechnology industry distribution chart, RBC Bioscience ranks #465 out of 732 companies for Gross Margin %. This places RBC Bioscience in the lower half of its industry. The industry median Gross Margin % is 60.91. RBC Bioscience's value of 45.48% is 25.3% below this benchmark. Historically, RBC Bioscience's own Gross Margin % has ranged from 41.38 to 52.22 over the past decade. While the company's 10-year median is 45.77 vs. the industry median of 60.91, RBC Bioscience has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Gross Margin % for a Biotechnology company?
The median Gross Margin % among Biotechnology companies is 60.91, based on 732 companies in the industry. Companies in the top quartile (top 25%) have a Gross Margin % significantly above this median, while those in the bottom quartile fall well below. However, Gross Margin % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. RBC Bioscience's current Gross Margin % of 45.48% is 25.3% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Gross Margin % mean?
A high Gross Margin % can signal that a stock is expensive relative to its fundamentals. Gross margin is the ratio of total gross profit to net sales. View historical data on RBC Bioscience and its competitors. For the Biotechnology industry, the median Gross Margin % is 60.91 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. RBC Bioscience's current Gross Margin % is 45.48%, which is near median its own 10-year median of 45.77. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is RBC Bioscience stock overvalued right now?
Based on GuruFocus' analysis, RBC Bioscience (ROCO:6848) is currently considered Fairly Valued. The stock's GF Value™ is NT$19.91, compared to a current price of NT$20.50 — trading 3% above its estimated fair value. The current Gross Margin % is 45.48%, which is near median its 10-year median of 45.77 and 25.3% below the Biotechnology industry median of 60.91. RBC Bioscience's overall GF Score™ is 76/100 with 7 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Gross Margin % calculated?
Gross Margin % is calculated from a company's financial statements. For RBC Bioscience (ROCO:6848), the current Gross Margin % is 45.48% as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is RBC Bioscience (ROCO:6848) Overvalued in 2026?
Based on GuruFocus' analysis, RBC Bioscience stock appears to be overvalued.
The current stock price of NT$20.50 is trading 3% above its estimated GF Value™ of NT$19.91.
GuruFocus considers RBC Bioscience to be Fairly Valued.
Key valuation signals for ROCO:6848:
Gross Margin %: 45.48% (near median its 10-year median of 45.77)
GF Value™: NT$19.91 vs. price of NT$20.50 (3% above fair value)
Industry Position: 25.3% below the Biotechnology median (#465 of 732)
No single metric tells the full story. See the ROCO:6848 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
RBC Bioscience Corp is a bio-sciences company. Its products include the manufacture and sale of molecular biological medical diagnosis and research reagents, gene extraction automatic testing instruments, and gene extraction reagent tissues.
76GF Score
Get the complete analysis for ROCO:6848
Gross Margin % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
ROCO:6848 has been successfully added to your 
